In a novel attempt to understand the variations in DNA sequences underlying HLA class I alleles associated with HPV16-related CaCx, we determined the alleles by reconstructing SNP-based haplotypes from resequencing of the most polymorphic exons 2 and 3 of HLA-A, HLA-B and HLA-C. We also determined the impact of SNPs and transcriptional alterations of the genes on CaCx. A high density of SNPs was identified from resequencing. HLA expression was determined by real-time PCR. We identified that even a single associated HLA allele had many underlying SNP-based haplotypes. Out of the most frequent (5%) HLA class I alleles, HLA-B*40:06 and HLA-B*15:02 respectively imparted significant risk towards and protection from CaCx as well as HPV16 infection. Employing median-joining networks to detect clusters of sequence-variations for specific HLA alleles, we found the protective SNP-based signature, GAATTTA, in all SNP-based haplotypes of HLA-B*15:02 allele. The signature was derived from seven SNPs within HLA-B which were newly associated with the disease. Contrarily, similarly derived risk-signature, TTGCGCC, mapped only to 52% of SNP-based haplotypes of HLA-B*40:06 allele. This indicated that all SNP-based haplotypes underlying a particular associated HLA allele might or might not have a single signature of risk/protection. HLA-A, HLA-B and HLA-C expressions were downregulated among CaCx cases compared to asymptomatic infections and HPV-negative controls. HLA-A and HLA-B were repressed in both cases harbouring episomal and integrated HPV16, whereas HLA-C in only the latter. Novel genetic variations and differential downregulation-patterns of HLA class I have a significant bearing on HPV16-related CaCx pathogenesis.
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The class I Human Leukocyte Antigen (HLA), in the Major Histocompatibility Complex (MHC) of the short arm of chromosome 6 (6p21.3), is polygenic including HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. HLA class I molecules, expressed on the surface of nucleated cells, are glycoproteins of 45 kDa having three extracellular domains (a 1 , a 2 and a 3 ), a transmembrane domain and a cytoplasmic anchor-segment. The peptide-binding cleft, formed by the a 1 and a 2 domains, presents endogenous antigens of altered self-cells triggering cytotoxic T-lymphocyte (CTL) response. Different genetic variations at the peptide-binding cleft might influence antigen-presentation altering CaCx-risk. HLA-A, HLA-B and HLA-C, exhibit multiple codominant alleles formed by combinations of sequence-motifs generated by mutation, gene-conversion and recombination. Adding to the complexity, HLA is the most polymorphic region of human genome and, HLA-B harbours the highest number of polymorphisms. 2 HLA-domain and SNP (single nucleotide polymorphism)-domain of research, although distinct from each other, use some overlapping terminology. 3 An HLA locus is equivalent to an HLA gene. Each locus (HLA-A, HLA-B and HLA-C) can have thousands of alleles (http://hla.alleles.org). An HLA haplotype is a combination of different HLA alleles at different loci in the same chromosome (either paternal or maternal). 4, 5 In the SNP-domain, there are four possible alleles (A/T/C/G) at each SNP-locus, biallelic type (with minor allele frequency exceeding 1%) being the most predominant. 6 Orderly combinations of nucleotides at SNP-loci on the same chromosome (paternal or maternal) are also called 'haplotypes'. 6 These can be constructed from genotype data at multiple SNP-loci. To avoid any confusion, haplotype derived from SNPs will be termed as 'SNP-based haplotype' henceforth in the text. Conflicting associations of different HLA alleles have been reported in CaCx pathogenesis, which can be explained by populationspecific linkage diequilibrium (LD) and also HPV variantspecific antigen-presentation. [7] [8] [9] [10] The significance of HLA class I-mediated CTL responses to viral and tumor antigens necessitates elaborate epidemiological research on HLA class I alleles and their underlying SNPs.
In the present study, we performed sequence-based typing (SBT) of HLA-A, HLA-B and HLA-C alleles by manual curation of SNPs from sequence-data of exons 2 and 3, the highest polymorphic regions coding the peptide-binding cleft. 11 We included the SNP-based allelic data for case-control association-study in the context of HPV16-positive CaCx as well as asymptomatic HPV16 infection. In a novel approach, our study has derived HLA class I alleles from SNP-based haplotypes, which were reconstructed from unphased genotype-data at SNP loci of exons 2 and 3 using PHASE algorithm and subsequent comparison with HLA allele-database. 12, 13 Loss of HLA-expression in CaCx can occur at genetic or transcriptional levels or, by protein-protein interactions. There are reports showing repression of HLA class I heavy chain promoter by E7 protein of HPV16 and 18 and loss of HLA class I by E5 of HPV16. 14, 15 However, there is a lack of available reports on probable differential downregulation of HLA class I expression with respect to CTL-stimulatory HLA-A and HLA-B and, NK (natural killer)-cell inhibitory HLA-C. 16 In our study, we aimed to address the aforementioned aspects of HLA class I genetic and transcriptional variations in the context of HPV16-related CaCx pathogenesis. The well known highly polymorphic nature of the classical HLA class I genes, prompted us to test whether associated HLA alleles could bear specific signatures of risk or protection derived from underlying SNPs. Thereby, we also tested associations of SNPs and potential SNP-based signatures from most polymorphic exons of HLA-A, HLA-B and HLA-C with the disease. We also investigated whether expressions of HLA-A, HLA-B and HLA-C were equally or differentially downregulated in modulating the disease risk.
Materials and Methods

Sample collection and HPV16-detection
Biological specimens were collected from women of similar ethnic and geographical background, at three institutes in Kolkata, India, with informed consent approved by the institutional ethical committees. The study included tissue-biopsy samples from (i) CaCx patients attending the cancer referral hospital, Saroj Gupta Cancer Centre and Research Institute (Kolkata), (ii) women hysterectomized for prolapse/fibroid/cyst attending the Department of Gynecology and Obstetrics, Calcutta Medical College and Hospital (Kolkata) and, cervical scrapes from women attending the Reproductive and Child Health Care Clinic, Child In Need Institute (CINI, Pailan, South 24 Parganas). The samples were categorized into HPV16-positive CaCx cases, HPV16-positive non-tumors (asymptomatic infection histopathologically confirmed as non-malignant) and HPV-negative controls. The mean ages of the three categories were 45.69 6 10.24, 44.54 6 11.13 and 44.31 6 9.32 years, respectively.
Details regarding sample collection and storage, DNA/RNA isolation, PCR-based HPV16-detection, reverse transcription, and identification of HPV16 integration-status are described in previous communications from our laboratory. 17, 18 HPV16-positive cases were further divided into those harboring episomal viral genomes (either purely episomal or a mixture of episomal and integrated) and, those without episomal genomes harboring only integrated genomes.
HLA class I genotyping and allele classifications PCR, sequencing, data-curation. Each initial PCR of exons 2 and 3 of HLA-A, HLA-B and HLA-C was performed on 100 ng template DNA. The reaction mixture contained 10x
What's new? Variations in human leukocyte antigen (HLA) genes are suspected of altering human papillomavirus (HPV) antigen presentation, potentially increasing or decreasing risk of cervical carcinoma (CaCx). The degree to which different HLA alleles influence CaCx development, however, is unclear. This analysis of single nucleotide polymorphisms (SNPs) and SNP-based haplotypes reveals the existence of numerous underlying variations among CaCx-associated HLA class I alleles. Of the most frequent alleles, however, only HLA-B*40:06 was significantly associated with CaCx risk and HLA-B*15:02 significantly linked to protective effects. Analyses further revealed varying patterns of downregulation in HLA-A, HLA-B, and HLA-C expression, among HPV16-positive CaCx samples with respect to HPV16 genome-integration.
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PCR buffer (Roche, Switzerland; 50 mM KCl, 50 mM TrisHCl (pH 8.3), 50 mM (NH 4 ) 2 SO 4 ) alongwith 2 mM MgCl 2 , 100 lM dNTP, 40 ng primers, 1.5 U Taq polymerase (Roche, Switzerland) for HLA-A, 1 mM MgCl 2 , 50 lM dNTP, 10 ng primers, 1.0 U Taq polymerase for HLA-B and, 1 mM MgCl 2 , 30 lM dNTP, 9 ng primers, 1.0 U Taq polymerase for HLA-C. HLA-A and HLA-C were initially amplified for 14 cycles with annealing at 758C for 55 sec and 728C for 30 sec, respectively, with a reduction of 0.58C per cycle. Subsequently these were amplified for 25 cycles with annealing at 688C for 55 and 30 sec, respectively. HLA-B was amplified for 35 cycles with annealing at 498C for 45 sec. Each PCR included denaturation at 958C for 30 seconds and elongation at 728C for 50 sec. The exons 2 and 3 were separately amplified by nested PCR on initial PCR-products. The reaction mixtures contained 10x PCR buffer alongwith 1.5 mM MgCl 2 , 50 lM dNTP, 10 ng (exon2) or 15 ng (exon3) primers and 1.0 U Taq polymerase for both HLA-A and HLA-C, while, 1.5 mM MgCl 2 , 25 lM dNTP, 2 ng primers, 0.5 U Taq polymerase for HLA-B. HLA-A exon 2 was amplified for 25 cycles with annealing at 708C for 30 sec. HLA-A exon 3, both HLA-B exons and HLA-C exon 2 were initially amplified for 14 cycles with annealing at respectively 70, 75, and 758C for 30 sec each with a reduction of 0.58C per cycle. Subsequently, these exons were amplified for 22, 22 and 25 cycles with annealing at respectively 63, 68, and 688C for 30 sec each. HLA-C exon 3 was amplified for 25 cycles with annealing at 708C for 30 sec. Each PCR included denaturation at 948C and elongation at 728C for 30 sec each. The nested PCR-products were treated with 0.6 U Exonuclease I and 1.6 U Shrimp Alkaline Phosphatase at 378C for 1 hr and subsequent enzyme-inactivation at 808C for 20 min. The cleaned DNA was used for sequencing with 25 ng primer, and BigDye V R Terminator v3.1 cycle sequencing kit (Applied Biosystems, USA) on ABI-3100 sequencer. The PCR included 35 cycles with denaturation, annealing and elongation at respectively 96, 55, and 728C for 30 sec each. The primers sequences (from SBT protocol of International Histocompatibility Working Group (IHWG)) are provided in Supporting Information Table 1 . The data generated were analyzed by PHREDPHRAP and CONSED (http://www.mbt.washington. edu/phrap.docs/phred.html). The electropherograms of resulting sequence-assemblies were manually scanned for identification of SNP loci and curation of genotype-data. The reference sequence considered was NC_000006.11, the chromosome 6 reference from GRCh37.p13 primary assembly (www.ncbi.nlm.nih.gov).
Statistical analysis for the study on SNPs in exons 2 and 3 of HLA class I genes. Frequency estimation of SNP-based alleles, Hardy-Weinberg Equilibrium testing and, associationtesting were performed with PLINK (http://pngu.mgh.harvard. edu/purcell/plink/). 19 False discovery rate (FDR) was used for multiple-testing correction. 20 Linkage disequilibrium was measured by HAPLOVIEW (http://www.broad.mit.edu/mpg/ haploview/). 21 Functional effect of a significantly associated SNP was estimated by PolyPhen-2 (http://genetics.bwh. harvard.edu/pph2/).
HLA class I allele-prediction, association-testing and frequency-estimation. SNP-based haplotypes underlying HLA alleles were reconstructed from both biallelic and multiallelic SNPdata with 95% genotyping-rate, which included 158, 165 and 147 samples for HLA-A, HLA-B and HLA-C, respectively (Supporting Information Tables 2a and 2b) , by PHASE v2.1.1 (http://depts.washington.edu/uwc4c/express-licenses/assets/ phase/). 12 Reference coding sequence was inserted in between consecutive SNP loci for each SNP-based haplotype by Rlanguage program (www.r-project.org), which can be made available on request. The resulting sequence corresponding to each SNP-based haplotype matched with a specific HLA class I allele (with >99% homology), using BLAST tool in IMGT/ HLA database (www.ebi.ac.uk/imgt/hla/). The method of HLA allele-prediction has been detailed in Supporting Information Figure 1 . Total number of HLA alleles, as well as SNP-based haplotypes, was double the sample-size because each individual had two alleles corresponding to two SNPbased haplotypes (on paternal and maternal chromosomes). Signature SNP-based haplotypes were reconstructed from significantly associated biallelic SNPs only. FDR was used for multiple-testing correction. 20 Median-joining (MJ) networks. SNP-based haplotypes corresponding to HLA-A, HLA-B and HLA-C were clustered by Median-Joining Network (http://www.fluxus-engineering.com/ sharenet.htm). 22 In a network, each node represented a SNPbased haplotype where node-size represented its frequency. Distance between two SNP-based haplotypes depicted minimum number of mutations in between. The SNP-based haplotype counts for cases, controls and HPV16-positive nontumors were colour-coded within each node. DNA sequence conservation across the three HLA class I genes were assessed by alignment with the orthologous primate reference sequences, viz., ancestral chimpanzee SNP-based haplotype (PATR-A, PATR-B and PATR-C from NC_006473.3) (www.ncbi.nlm.nih. gov). 23 HLA-A, HLA-B and HLA-C mRNA expressions HLA class I gene-expression was determined by qRT-PCR analysis. The RT-PCR mixture contained 2X Power SYBR V R Green PCR Master Mix (Applied Biosystems, USA), 25 ng primers and 103 diluted cDNA. Glyceraldehyde 3-phophate dehydrogenase (GAPDH) was used as an internal control. The PCRs included UDP-N-glycosylase-activation (508C; 2 min), initial denaturation (958C; 10 min), 40 cycles of denaturation (958C), annealing (578C) and elongation (728C) for 30 sec each. The primer-sequences are provided in Supporting Information Table 1 . Comparative C T analyses provided fold-change data. Each assay was duplicated along with three nontemplate controls. Normalized DC T values were compared by t test and FDR was used for multiple-testing correction.
20,24
Results
HLA class I allele-based association-testing HLA class I typing revealed 29 HLA-A, 54 HLA-B and 28 HLA-C alleles, which are described in Supporting Information Tables 3-5 , respectively. HLA alleles with frequency 5% were included in association-testing. Thereby, we included eight HLA-A alleles [A*11:12 (22.468%), A*33:01 (14.873%), A*24:02 (14.557%), A*01:01 (7.911%), A*02:03 (6.962%), A*02:04 (6.646%), A*68:01 (6.646%) and A*02:11 (Table 1) . HLA-A and HLA-C alleles did not depict any significant association. Details of all HLA alleles with frequency 5%, are provided in Supporting Information Table 6 .
Evolutionary analysis of SNP-based haplotypes corresponding to HLA class I alleles and their distribution among various categories of cervical samples employing median-joining (MJ) networks Median joining network analysis provided an overview of the SNP-based haplotypes reconstructed from genotyping data, separately for each gene (HLA-A, HLA-B and HLA-C). The networks ( Fig. 1 corresponding to HLA-A and HLA-C and Fig. 2 corresponding to HLA-B) share common features like very few high frequency nodes of SNP-based haplotypes, large number of moderate and low frequency nodes connected to the high frequency nodes resulting in partial local star-like phylogenies within each large network. Besides, the ancestral chimpanzee SNP-based haplotype appeared to be many mutational steps away from the human modal SNP-based haplotypes. These observations reflect purifying selections unique to the humans, since the separation of the human and chimpanzee lineages. 23 As depicted in Figures 1 and 2 , several virtual clusters were evident within each HLA class I network, and the SNPbased haplotypes within any virtual cluster matched with a specific HLA allele. The SNP-based haplotypes not included within any cluster represented rare HLA alleles. HLA-A network showed 10 such allele-specific clusters (Fig. 1a) . The SNP-based haplotypes in cluster-1, -2, -3, -4, -5, -6, -7, -8, -9 The SNP-based signature haplotypes comprise of the following SNPs in order: rs1131170 (G > T), rs1050518 (A > T), rs1050570 (G > A), rs12721827 (C > T), rs41556312 (T > G), rs1050379 (C > T) and rs1050654 (A > C). n 5 sample size; MAF 5 minor allele frequency; OR 5 odds ratio; CI 5 confidence interval; SE 5 standard error.
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allele-specific clusters (Fig. 1b) . The SNP-based haplotypes in cluster-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13 and -14 matched to HLA-C alleles C*06:02, C*12:03, C*12:02, C*04:03, C*07:26, C*07:01, C*07:02, C*07:04, C*04:01, C*15:02, C*14:44, C*01:02, C*03:02 and C*08:01, respectively.
The significantly associated protective allele, HLA-B*15:02 (cluster-4), and risk-allele, HLA-B*40:06 (cluster-10), were accordingly found to be less-represented and over-represented among cases, in the HLA-B network. In HLA-A network, the major node of HLA-A*24:02 (cluster-3), an evolutionarily recent cluster, generated many rare SNP-based haplotypes represented only among cases. The cluster corresponding to HLA-A*33:01 visually portrayed a protective nature, but lacked statistical significance after multiple-test correction.
SNP-based association-testing
We included a total of 33 HLA-A, 52 HLA-B and 28 HLA-C biallelic SNPs in association-testing among 158, 165 and 147 (Table 2 ) among the cases compared to the controls. CaCx risk associated with over-representation of the minor alleles at rs1131170 (G > T) (OR 5 3.36; CI 5 1.60-7.03; p age-adjusted,corrected 5 0.039) and rs41556312(T > G) (OR 5 3.10; CI 5 1.54-6.25; p age-adjusted,corrected 5 0.039) ( Table 2) was enhanced among HPV16-positive cases compared to asymptomatic infection. All associated HLA-B SNP-based minor alleles, whether susceptible or protective, accounted for nonsynonymous changes. The change from leucine to arginine at rs41556312 (T > G) was predicted as 'probably damaging' for HLA-B protein function (prediction confidence score 5 0.996) by PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) (Supporting Information Fig. 4) , specifically of the HLA-B alleles harbouring this SNP.
Association-testing of SNP-based signatures and mapping of such signatures within associated HLA alleles
We reconstructed 31 potential signature SNP-based haplotypes (Supporting Information Table 7 ) from the significant biallelic HLA-B SNPs, irrespective of HLA-B alleles. Of these, we tested six with frequency 5% for association with CaCx compared to asymptomatic infection or HPV-negative controls. The signatures were constructed with the following order of the SNPs: rs1131170 (G > T), rs1050518 (A > T), rs1050570 (G > A), rs12721827 (C > T), rs41556312 (T > G), rs1050379 (C > T) and rs1050654 (A > C). We found the signature, TTGCGCC, to be significantly over-represented among both CaCx compared to controls (OR 5 5.785; CI 5 1.87-17.92; p age-adjusted,corrected 5 0.012) and asymptomatic infection (OR 5 3.498; CI 5 1.42-8.62; p age-adjusted,corrected 5 0.021) ( Table  1 ). The signature, GAATTTA, was significantly underrepresented among CaCx compared to control (OR 5 0.117; CI 5 0.029-0.47; p age-adjusted,corrected 5 0.009) and asymptomatic infection (OR 5 0.141; CI 5 0.037-0.54; p age-adjusted,corrected 5 0.024) ( Table 1 The relative gene expression is shown in Figure 3b . There was no significant difference in expressions of HLA-A, HLA-B and HLA-C, between HPV16-positive non-tumors and HPV-negative controls. The PCR-efficiencies of HLA genes and endogenous control, GAPDH, were similar (Supporting Information Fig. 5 ).
Expressions of HLA-A, HLA-B and HLA-C among episomal and integrated CaCx cases as compared to HPV-negative controls
We found downregulation of HLA-A and HLA-B, among cases harbouring exclusively integrated HPV16 genomes (Fig.  4a) , to be much higher in terms of fold change than those with episomal genomes (Fig. 4b) , when each was compared with respect to controls. Among the integrated cases, HLA-A (mean DC T 5 9.34 6 0.85) and HLA-B (mean 
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Discussion
In a novel attempt to understand the variations in the DNA sequences underlying HLA alleles associated with cervical carcinogenesis, we reconstructed SNP-based haplotypes from resequencing of the most polymorphic exons 2 and 3 of classical HLA class I genes. We manually identified 63, 94 and 50 single nucleotide variations (both biallelic and multiallelic) in the aforesaid exons of HLA-A, HLA-B and HLA-C, respectively, by resequencing (Supporting Information Table 2a) , and reconstructed SNP-based haplotypes from unphased genotype-data using PHASE software. 12 Hence, we combined SBT method with SNP-based haplotype-reconstruction to type HLA class I alleles. The matching HLA class I alleles, extracted from IMGT/HLA database, were resolved till the fourth position, that is second level of resolution addressing serological variation and non-synonymous changes according to HLA-nomenclature. 25 We relied on the PHASE-algorithm to predict the most probable SNP-based haplotype, in addressing an SBT-related ambiguity. 3 Genetic variations in epitope-binding exons were only considered and, those outside were beyond the scope of the study. A somewhat similar approach was described in a previous study, which employed SNP-genotyping data limited to reported SNPs only, unlike our approach. 26 We found that even a single associated HLA allele could have multiple underlying SNP-based haplotypes as also revealed by their clustering in median-joining networks, confirming an earlier report. 26 The networks facilitated visualization of the relatively frequent allelic clusters, their comprising SNP-based haplotypes along with probable disease-association. HLA-B*40:06 was overrepresented among HPV16-positive cases compared to either HPV-negative controls or HPV16-positive non-tumors, suggestive of its role in disease-progression from asymptomatic infection. Likewise, under-representation of HLA-B*15:02 among HPV16-positive cases potentially depicted its role in spontaneous regression of infection. In HLA-B network, all the SNPbased haplotypes in cluster-4, representing the protective allele B*15:02, encompassed the SNP-based signature, "GAATTTA" rendering protection from CaCx and HPV16 infection. However, 13 out of 23 (52%) SNP-based haplotypes in cluster-10, representing the risk-allele B*40:06, contained the SNP-based signature, "TTGCGCC" conferring risk toward CaCx and HPV16 infection. The SNP-based signatures reconstructed from significantly associated SNPs could be mapped to majority but not necessarily all of the underlying SNP-based haplotypes of a significantly associated HLA allele. These minimal SNP-based signatures could potentially be considered as markers of associated risk or protection of an HLA allele. In HLA-A network, the evolutionarily recent cluster-3 representing HLA-A*24:02, depicted many small nodes emanating from a larger node. Majority of the small nodes were representative of cases, potentially reflecting risk-signatures of these SNP-based haplotypes. Thus it appears that there could be multiple signatures borne by each HLA allele background. Identification of such signatures within an HLA allele could be achieved through analysis of larger sample sizes as well as employing deep sequencing technology.
Identification of only three HLA-A (3/155; 1.935%), one HLA-B (1/186; 0.537%) and one HLA-C (1/155; 0.645%) SNPbased haplotypes of frequency 5% (Supporting Information  Tables 3-5) , suggested the immense variability maintained by HLA class I genes to ensure clearance of pathogenic antigens at the population level. 3, 27 Need for a very large sample size was a limitation in conducting a study on the SNP-based haplotypes derived from such highly polymorphic genes. 28 In our study, we differed from an earlier finding from our laboratory showing a negative association of B*40:06 with the disease, which might be attributed to the relatively smaller sample-size (only six cancer cases) and the different assay employed in the previous study. 29 Our current study also differed from a report on western Indian population showing B*37:01 as risk and B*40:06 as protective alleles, although both possessed the B44 supertype of epitope-binding specificity. 30 Such difference could potentially be attributable to differences in study-populations and methods of HLA-typing. Our approach helped to distinguish different SNP-based haplotypes within the same B*40:06 allele. Such resolution was not achieved with PCR-SSO (sequence specific oligo) based HLA-typing, employed by the earlier studies.
HLA-B*15:02 and HLA-B*40:06 have been identified to belong to two different HLA supertypes B62 and B44, respectively. 31 Hence, these would differ with respect to binding capabilities of epitopes from HPV16 oncoproteins (E6 and E7 most importantly) in view of their enhanced expressions in cervical cancers. There are reports available which highlight that HLA-B*35 alleles, belonging to B07 and B62 supertypes, might be involved in HPV16 epitope-binding. 31, 32 A study employing direct identification of tumour antigens from cervical biopsy tissues, identified an E7 9-mer peptide as a dominant T-cell epitope that was presented by HLA-A*02:01 positive cervical squamous and adenocarcinomas, before and after adjuvant chemotherapy. 33 In our study, we failed to identify HLA-A*02:01 or HLA-B*35 to impart risk or protection to CaCx development. On the other hand, the B44 supertype, to which the risk HLA-B*40:06 belongs, has not been implicated in HPV16 epitope-binding. Interestingly, HLA-B*40:06 has been reported to bind peptides weakly, owing to the presence of a bulky Trp95 in its 'F' pocket. 34 Weak peptide-binding might result in inefficient antigenic presentation facilitating HPV16 persistence. HLA-B*40:06, which is also the most predominant HLA class I allele in Indian population, has also been implicated in other infections like tuberculosis and HIV. 34 Resequencing of the highly polymorphic exons of HLA class I genes in our study helped to identify and analyze a high density of SNPs in the context of HPV16-related CaCx pathogenesis. We found for the first time that the minor alleles of seven HLA-B SNPs were significantly associated with disease-risk or -protection, compared to either HPV-negative controls and/or asymptomatic infections. The associated minor alleles resulted in non-synonymous amino acid changes, which could possibly result in conformational changes of the HLA class I antigenbinding groove affecting its epitope-presenting potential. 7 The nonsynonymous change at rs41556312 (T > G) was predicted as "probably damaging" by PolyPhen-2.
Genome wide association studies (GWAS) from different populations have revealed association of different genic/ intergenic regions within MHC with cervical carcinoma. GWAS on Swedish population exhibited associations of rs2516448 (adjacent to MICA), rs9272143 (between HLA-DRB1 and HLA-DQA1) and rs3117027 (in HLA-DPB2) with cervical carcinoma. 35 The study also related the previously reported contradictory associations of B*0702 allele and DRB1*1501-DQB1*0602 haplotype to the joint effect of rs9272143 and rs2516448. 35 Another GWAS on European population found association of B*07 and B*1501 with squamous cell cervical carcinoma. 36 GWAS on Han Chinese population depicted associations of rs4282438 in HLA-DPB1/HLA-DPB2, intergenic rs927795 and, the non-MHC SNPs rs13117307 (at 4q12) and rs8067378 (at 17q12) with cervical cercinoma. 37 However, a Japanese GWAS failed to show any association. 38 Notably, none of such studies revealed the proportion of HPV16-positive cases separately, as opposed to our study focusing on HPV16-positive CaCx cases only. There has been a lack of consistency among such studies, and also between GWAS and candidate-geneapproaches. 36 Interestingly, role of HLA-B in cervical carcinogenesis was highlighted by another study based on exomesequencing in Norwegian and Mexican women, revealing seven inactivating somatic mutations in HLA-B. 39 The affected amino acid positions included the 35th amino acid, which was also affected by the significantly associated SNP rs1131170 (G > T) as highlighted in our study. Previous reports have shown that different platform based studies like GWAS and SBT kit-based association-study from the same population might suggest association of different HLA alleles/SNPs. 37, 40 Hence, instead of using SBT kit or genotyping of reported SNPs only, we resequenced the most polymorphic exons of HLA-A, HLA-B and HLA-C to identify all the single nucleotide variations (with 95% genotyping rate) within the study-group.
In conjunction with the proposed role of HLA class I genetic variations in HPV16 related cervical pathogenesis, we also explored association of HLA class I expression alterations. HLA-A, HLA-B and HLA-C were downregulated among HPV16-positive cases compared to HPV-negative controls and HPV16-positive non-malignant samples, supporting earlier reports.
14 Compared to HPV-negative controls, HLA-A and HLA-B were downregulated in both episomal and integrated HPV16-positive cases, while HLA-C downregulation was only observed among integrated cases. Several reports on presence of episomal genomes in CaCx cases from our laboratory and others have prompted exploring alternative mechanisms of carcinogenesis under the impact of episomal HPV16. 17, 41 In our study, we demonstrated for the first time that differential downregulation of HLA class I genes existed between episomal and integrated cases. To avoid NK-cell mediated killing of virus infected cells, viruses often opt for differential downregulation of HLA class I expression by repressing CTL-stimulatory HLA-A and HLA-B, but not NK-cell inhibitory HLA-C. 1, 16 Besides, HLA-C repression in integrated cases could be suggestive of inflammation-mediated carcinogenesis. 42 Differential levels of HLA class I repression between episomal and integrated cases was further reflected by the intensive downregulation of HLA-A and HLA-B in integrated cases, as opposed to episomal cases. This could be attributable to viral integration mediated expression of aberrant fusion-peptides, which evoke CTL response. Therefore, substantial repression of HLA class I would be necessary for viral survival in integrated cases.
In summary, our study revealed predisposing or protective genetic variations within classical HLA class I genes through an in-depth analysis of SNPs and SNP-based haplotypes. Networkbased analyses provided a visual representation of the available pool of HLA alleles, their underlying SNP-based haplotypes and nature of association with the disease, which might not be statistically significant owing to insufficient sample-size. We highlighted that majority but not necessarily all the SNP-based haplotypes underlying an associated HLA allele might use a single genetic signature (risk/protective) in directing the pattern of association of the HLA allele. Immune evasion through HLA class I downregulation among the CaCx cases was evident from our study, but more prominently among cases with integrated viral genomes. This was suggestive of differential mechanisms of immune evasion between episomal and integrated HPV16-positive cases. In sum, our findings highlight that apart from exonic sequence variations within HLA class I genes, variation in the expression of such genes could also have profound impact on CaCx pathogenesis. This calls for identification of regulatory single nucleotide variations and other categories of genetic variations even outside the exonic regions of HLA class I genes, which could best be achieved through Next Generation Sequencing, and have already been initiated in our laboratory. The findings from our study could further aid translational research on HLA-B specific screening for disease-risk, antigenic presentation of therapeutic peptide vaccines, and HPV16 integration-status oriented immunotherapy. Overall, the findings have significant bearing on the existing knowledge on association of HLA class I with the disease, along with the potential to trigger future research.
Cancer Genetics and Epigenetics
